India, Nov. 16 -- Shares of several biotech companies moved higher following clinical, corporate and development updates. CG Oncology advanced after positive Phase 3 bladder cancer data, CNS Pharmaceuticals gained on progress toward its first pipeline acquisition, Lexeo Therapeutics rose on encouraging gene therapy findings, and XORTX Therapeutics advanced after completing clinical drug manufacturing for its gout program.
Read on.....
CG Oncology, Inc. (CGON)
Shares of CG Oncology surged 18% on Monday after its Phase 3 PIVOT-006 trial of cretostimogene in non-muscle invasive bladder cancer met its primary endpoint, reducing the risk of cancer recurrence by 68% versus the control group. The treatment was generally well tolerated, with no ...